PDCD1 and neoplasm: Still, most studies rely on phenotypic markers as a surrogate for tumor reactivity during PD-1/PD-L1 blockade, and positive associations with T cell markers, such as CD39, Ki67, PD-1, TCF1, and CD103, have been reported (21, 32–36).